SLU-PP-332 vs SLU-PP-915
A research-focused comparison of two chemically distinct experimental pan-estrogen-related receptor agonists, including ERR pharmacology, chemical development, oral activity, mitochondrial research and the published preclinical evidence surrounding SLU-PP-332 and SLU-PP-915.
SLU-PP-332 and SLU-PP-915 are chemically distinct experimental small-molecule pan-ERR agonists. SLU-PP-332 is the earlier research compound that helped establish the experimental effects of pharmacological ERR activation. SLU-PP-915 emerged from subsequent medicinal-chemistry research and demonstrated oral activity in mice. Neither compound has established human clinical efficacy, dosing or safety.
SLU-PP-332 vs SLU-PP-915 at a Glance
Although their names are similar and both interact with the estrogen-related receptor family, SLU-PP-332 and SLU-PP-915 are not interchangeable compounds.
SLU-PP-332
An experimental synthetic pan-ERR agonist used in preclinical research involving skeletal muscle, mitochondrial biology, oxidative metabolism and exercise-associated transcriptional responses.
SLU-PP-915
A chemically distinct pan-ERR agonist developed during later medicinal-chemistry research and subsequently investigated for oral activity in preclinical mouse models.
SLU-PP-332 vs SLU-PP-915: Key Differences
The primary differences involve chemical development, pharmacological profile and reported pharmacokinetic properties rather than simply one compound being a different concentration of the other.
| Research Characteristic | SLU-PP-332 | SLU-PP-915 |
|---|---|---|
| Compound Type | Synthetic small molecule | Synthetic small molecule |
| Peptide? | No | No |
| Primary Pharmacology | Pan-ERR agonist | Pan-ERR agonist |
| ERR Targets | ERRα, ERRβ and ERRγ | ERRα, ERRβ and ERRγ |
| Development | Earlier benchmark research agonist | Later chemically distinct research agonist |
| Published Receptor Profile | Pan-ERR activity with greater potency toward ERRα in published experimental assays | Potent activity across the estrogen-related receptor family in published medicinal-chemistry research |
| Oral Activity in Mice | Lack of oral bioavailability identified as a research limitation | Oral activity demonstrated |
| Research Focus | ERR signaling, skeletal muscle, oxidative metabolism, mitochondrial biology | ERR signaling, medicinal chemistry, oral exposure, exercise-associated biology |
| Human Clinical Efficacy | Not established | Not established |
| Established Human Dose | No | No |
What Are SLU-PP-332 and SLU-PP-915?
SLU-PP-332 and SLU-PP-915 are experimental synthetic small molecules developed to activate members of the estrogen-related receptor (ERR) family.
The major members of this nuclear-receptor family are ERRα, ERRβ and ERRγ. Despite their name, estrogen-related receptors are distinct from classical estrogen receptors.
ERRs participate in transcriptional programs associated with cellular energy metabolism. Research has linked ERR signaling with mitochondrial biology, oxidative phosphorylation, fatty-acid oxidation and other metabolic pathways.
Important classification: neither SLU-PP-332 nor SLU-PP-915 is a peptide. Both are synthetic small molecules studied as experimental pan-ERR agonists.
How Pan-ERR Agonism Is Being Studied
Both compounds are described as pan-ERR agonists because their experimental activity extends across multiple estrogen-related receptor isoforms rather than being restricted to a single ERR target.
ERR Agonist
ERRβ
ERRγ
Signaling
Mitochondrial Research
Synthetic ERR agonists therefore provide researchers with chemical tools for investigating how pharmacological activation of these nuclear-receptor pathways influences cellular energy metabolism and related biological processes.
SLU-PP-332 Research Profile
SLU-PP-332 is an experimental synthetic small molecule characterized in published research as an agonist of ERRα, ERRβ and ERRγ.
The compound became particularly notable through preclinical research examining whether pharmacological ERR activation could produce selected transcriptional and metabolic responses that overlap with biological responses to aerobic exercise.
Pan-ERR Pharmacology
Published experimental assays characterize SLU-PP-332 as active across the ERR family, with greater potency toward ERRα reported in the original characterization.
Skeletal-Muscle Research
Preclinical research has investigated oxidative skeletal-muscle characteristics and ERR-dependent exercise-associated transcriptional responses.
Mitochondrial Biology
Experimental work has examined mitochondrial function, cellular respiration and pathways associated with oxidative energy metabolism.
Pharmacokinetic Limitation
Later published research identifies lack of oral bioavailability as an important limitation of SLU-PP-332.
Explore SLU-PP-332 Research Material
View current research formats, specifications and SLU-PP-332 catalog information.
SLU-PP-915 Research Profile
SLU-PP-915 is a later, chemically distinct pan-ERR agonist identified during medicinal-chemistry research focused on developing additional potent estrogen-related receptor agonists.
The medicinal-chemistry program investigated alternative chemical scaffolds and how structural modifications influenced ERR activity, metabolic stability and other properties relevant to experimental pharmacokinetics.
Distinct Chemistry
SLU-PP-915 is not another concentration or formulation of SLU-PP-332. It is a chemically distinct experimental molecule.
Pan-ERR Activity
Published medicinal-chemistry research characterizes SLU-PP-915 as a potent agonist with activity across the estrogen-related receptor family.
Oral Activity in Mice
A major research distinction is the demonstration of biological activity following oral administration of SLU-PP-915 in mouse experiments.
Exercise-Associated Research
Published mouse research has investigated aerobic exercise capacity following oral exposure to SLU-PP-915.
Why Was SLU-PP-915 Developed?
SLU-PP-332 provided researchers with an experimental chemical tool for investigating pharmacological pan-ERR activation. However, subsequent research identified a significant pharmacokinetic limitation: SLU-PP-332 lacks oral bioavailability.
Medicinal-chemistry research therefore investigated alternative chemical scaffolds capable of maintaining potent ERR agonist activity while changing properties relevant to metabolic stability and systemic exposure.
SLU-PP-915 emerged from this later research and subsequently demonstrated biological activity following oral administration in mouse experiments.
Scientific distinction: SLU-PP-915 should not simply be described as a “stronger SLU-PP-332.” The compounds differ in chemical structure, pharmacological characterization and reported pharmacokinetic properties.
Oral Bioavailability: A Major Research Difference
Oral activity represents one of the clearest experimentally reported differences between SLU-PP-332 and SLU-PP-915.
Published research identifies lack of oral bioavailability as a limitation of SLU-PP-332. Later research characterized SLU-PP-915 as a chemically distinct pan-ERR agonist and demonstrated biological activity following oral administration in mice.
This distinction concerns experimental pharmacokinetics. Oral activity in a mouse model does not establish human oral pharmacokinetics, efficacy, dosing or safety.
SLU-PP-332, ERR Signaling and PGC-1α
SLU-PP-332 is sometimes described online as a “PGC-1α activator.” That shorthand can be misleading when presented as its direct primary molecular target.
The more precise pharmacological characterization is that SLU-PP-332 is a synthetic ERRα/β/γ agonist. Estrogen-related receptors operate within broader transcriptional networks involving PGC-1 family coactivators and participate in regulation of genes associated with oxidative metabolism and mitochondrial biology.
PGC-1-related signaling is therefore relevant to the biological context, but SLU-PP-332 is more precisely identified by its experimentally characterized pan-ERR agonist pharmacology.
Are SLU-PP-332 and SLU-PP-915 Exercise Mimetics?
Both compounds appear in scientific research examining the concept of pharmacological exercise mimetics.
An exercise mimetic is an experimental intervention intended to activate selected molecular pathways that overlap with biological adaptations associated with physical exercise.
ERR signaling is relevant to this research because these nuclear receptors participate in transcriptional regulation of mitochondrial and oxidative energy metabolism.
The term should not be interpreted literally. Physical exercise produces broad cardiovascular, neurological, musculoskeletal and metabolic adaptations. Activation of a selected transcriptional network does not establish reproduction of all those effects.
ERR Agonists and Mitochondrial Research
The relationship between estrogen-related receptor signaling and cellular energy metabolism is a major reason experimental ERR agonists have attracted scientific interest.
ERR-regulated transcription participates in biological pathways associated with mitochondrial function, oxidative phosphorylation, fatty-acid metabolism and cellular energy utilization.
These pathways are especially relevant in tissues with substantial energy requirements, making synthetic ERR agonists useful chemical tools for investigating metabolic adaptation and mitochondrial biology.
Metabolism of SLU-PP-332 and SLU-PP-915
Analytical research published in 2026 further characterized both experimental compounds using liquid chromatography–high-resolution tandem mass spectrometry and in-vitro metabolic systems involving human liver S9 fractions and human liver microsomes.
The investigators reported nine metabolites for SLU-PP-332, including six Phase-I metabolites and three Phase-II conjugates.
For SLU-PP-915, seven Phase-I transformation products were reported in the experimental systems studied.
This work contributes to analytical characterization and metabolite identification. Because these experiments used in-vitro liver-derived systems, the findings should not be interpreted as human clinical pharmacokinetic or safety data.
What Do We Know About Human Use?
The evidence discussed on this page is preclinical.
Laboratory and animal findings cannot establish human efficacy, appropriate dosing, long-term safety or clinical outcomes. Exercise-capacity and metabolic findings from mouse experiments must therefore remain explicitly identified as preclinical research.
Royal Peptides presents these compounds and related scientific literature for laboratory research reference. Research materials are not intended for human consumption.
What Is the Main Difference Between SLU-PP-332 and SLU-PP-915?
From a research perspective, one of the clearest distinctions is pharmacokinetic rather than simply pharmacodynamic. Both compounds interact with the ERR family, but SLU-PP-915 emerged from a different chemical series and demonstrated oral activity in preclinical mouse research.
SLU-PP-332 remains scientifically important because it helped characterize the experimental consequences of pharmacological pan-ERR activation. SLU-PP-915 extended this research with a chemically distinct scaffold and different properties relevant to oral exposure in mice.
For that reason, describing SLU-PP-915 simply as a more powerful version of SLU-PP-332 oversimplifies the published evidence.
SLU-PP-332 vs SLU-PP-915 FAQ
What is the difference between SLU-PP-332 and SLU-PP-915?
Both are experimental synthetic pan-ERR agonists, but they are chemically distinct. A particularly important reported difference is that SLU-PP-915 demonstrated oral activity in mouse research, whereas lack of oral bioavailability has been identified as a limitation of SLU-PP-332.
Is SLU-PP-915 an upgraded version of SLU-PP-332?
It is more accurately described as a later, chemically distinct ERR agonist developed through medicinal-chemistry research. It is not simply another formulation or concentration of SLU-PP-332.
Is SLU-PP-915 orally bioavailable?
Published preclinical research reports oral activity for SLU-PP-915 in mice. This does not establish human oral pharmacokinetics, efficacy, dosing or clinical use.
Is SLU-PP-332 orally bioavailable?
Published research identifies lack of oral bioavailability as a limitation of SLU-PP-332. This contributed to interest in chemically distinct ERR agonists with different pharmacokinetic properties.
Are SLU-PP-332 and SLU-PP-915 peptides?
No. Both are synthetic small molecules rather than peptide chains.
Is SLU-PP-332 a PGC-1α activator?
Its more precise primary classification is a synthetic ERRα/β/γ agonist. PGC-1 family coactivators participate in broader transcriptional networks relevant to ERR signaling, but PGC-1α should not be presented as the compound's direct primary molecular target.
What does ERR stand for?
ERR stands for estrogen-related receptor. ERRα, ERRβ and ERRγ are nuclear receptors involved in transcriptional regulation of cellular energy metabolism.
Why are these compounds discussed as exercise mimetics?
ERR signaling participates in metabolic pathways that are also influenced by aerobic exercise. Experimental pharmacological activation of these pathways has therefore been investigated within the exercise-mimetic research concept. This does not establish that either compound substitutes for physical exercise in humans.
Have SLU-PP-332 or SLU-PP-915 demonstrated human clinical efficacy?
The published evidence discussed here is preclinical. Laboratory and animal findings do not establish human clinical efficacy, dosing or safety.
Scientific References
-
Billon C, et al. (2023).
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute
Aerobic Exercise Response and Enhances Exercise Capacity.
ACS Chemical Biology.
View on PubMed → -
Hampton CS, et al. (2023).
Development and pharmacological evaluation of a new chemical
series of potent pan-ERR agonists and identification of
SLU-PP-915.
View full article at PubMed Central → -
Billon C, et al. (2026).
An orally active estrogen receptor-related receptor agonist,
SLU-PP-915, enhances aerobic exercise capacity.
Journal of Pharmacology and Experimental Therapeutics.
View on PubMed → -
Möller GM, et al. (2026).
In Vitro Metabolism and Analytical Characterization of
SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With
Doping Potential.
Rapid Communications in Mass Spectrometry.
View on PubMed →
